JOURNAL OF NEUROTRAUMA, 2009 · DOI: 10.1089=neu.2009.0954 · Published: December 1, 2009
Following spinal cord injury (SCI), the adult mammalian central nervous system (CNS) has limited ability to regenerate axons, resulting in permanent neurological deficits. One of the reasons is thought to be the presence of myelin-associated inhibitors, such as oligodendrocyte myelin glycoprotein (OMgp). This study created a specific OMgp polyclonal antibody to investigate OMgp expression after SCI. The study found increased OMgp mRNA and protein levels after SCI. OMgp was found localized in neurons and oligodendrocytes. The research suggests that OMgp may play a role in inhibiting axonal regeneration after spinal cord injury. By understanding OMgp's role, future treatments might target this molecule to promote nerve repair.
OMgp could be a potential therapeutic target for promoting axonal regeneration after SCI.
The prolonged elevation of OMgp matches well with the progression of spinal cord secondary injury.
Targeted treatment of OMgp in neurons and oligodendrocytes might improve outcomes after SCI.